Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 203Lymphoid 36Myeloid 35Classical hematology 12Gastrointestinal 7Plasma cell 4Thoracic 2Sarcoma 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Idarubicin × Thoracic × Clear all
NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06483347 2024-07-03

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡